LSPedia 的全球序列化系列
序列化不是一刀切的。由于美国、欧盟、亚洲和中东的规定各不相同,公司必须应对复杂的要求网络。您为全球合规做好准备了吗?
.png)
欢迎来到 LspEdia,在这里,创新与奉献精神相结合。
如果你热衷于有所作为并在协作环境中茁壮成长,LspEdia 就是你的不二之选。

序列化不是一刀切的。由于美国、欧盟、亚洲和中东的规定各不相同,公司必须应对复杂的要求网络。您为全球合规做好准备了吗?
如果你热衷于有所作为并在协作环境中茁壮成长,LspEdia 就是你的不二之选。
LSPedia is here to help.
In June 2025, the FDA issued a warning letter to a U.S.-based wholesale distributor that failed at nearly every level of DSCSA compliance. We're not naming names, but the violations speak volumes.
This wasn’t about confusing rules or a gray area. This was about a distributor ignoring the basics — and now facing the consequences. 15 days to reply to the notification with a comprehensive plan of action that satisfies the FDAs concerns, or face the consequences.
What Went Wrong
Want to know more? The full 483 warning letter is posted on the FDA’s website here.
The Message Is Clear
The FDA isn’t warning anymore. It’s enforcing.
If your systems can’t validate licenses, verify product, respond to suspect events, and produce transaction data on demand, you are not ready. And waiting any longer is a risk you can’t afford.
Where LSPedia Comes In
We help trading partners pharmaceutical manufacturers, distributors and dispensers get ahead of enforcement, not scramble after it.
Our OneScan platform gives youprovides:
No gaps. No guesswork. Full DSCSA readiness.
Don’t let your name be the next one in an FDA warning letter.
Talk to our team today and see how LSPedia keeps you compliant, protected, and prepared.